Log in to your Inderes Free account to see all free content on this page.

Biosergen

10.10 SEK

-8.18 %

Less than 1K followers

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-8.18 %

-73.42 %

-74.75 %

-74.44 %

-80.65 %

-69.58 %

-86.44 %

-

-97.27 %

Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.

Market cap

23.72M SEK

Turnover

115.96K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

6.5.

2026

Interim report Q1'26

19.5.

2026

General meeting '26

18.8.

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Press releaseyesterday

BioStock: Biosergen halts BSG005 development

Regulatory press release4/4/2026, 7:00 PM

Biosergen AB: Biosergen Pauses Development of BSG005

Regulatory press release2/10/2026, 7:30 AM

Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/20/2025, 7:30 AM

Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen

Press release11/19/2025, 1:54 PM

BioStock: Biosergen comments on continued progress in the third quarter

Regulatory press release11/19/2025, 7:30 AM

Biosergen AB: Biosergen publishes interim report for the third quarter 2025

Regulatory press release10/28/2025, 7:30 AM

Biosergen AB: Biosergen's Nomination Committee appointed

Press release9/22/2025, 11:43 AM

BioStock: ECDC sounds alarm on C. auris – Biosergen eyes role in containment

Press release9/17/2025, 10:04 AM

Carlsquare: Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe

Press release9/2/2025, 1:40 PM

Carlsquare: Research update Biosergen: Ongoing development going according to plan

Press release8/21/2025, 7:52 AM

BioStock: Biosergen’s CEO on the preparations for the next clinical phase

Regulatory press release8/20/2025, 6:30 AM

Biosergen AB: Biosergen publishes its interim report for the second quarter 2025

Press release7/25/2025, 10:16 AM

BioStock: Biosergen strengthens executive team amid clinical momentum

Regulatory press release7/24/2025, 12:12 PM

Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer

Regulatory press release6/11/2025, 10:01 AM

Bulletin from the annual general meeting in Biosergen AB (publ)

Press release5/23/2025, 8:00 AM

Carlsquare: Research update Biosergen: Stable quarter with exciting news around the corner

Press release5/21/2025, 1:47 PM

BioStock: Biosergen advances antifungal drug with strong Q1 results

Regulatory press release5/21/2025, 6:30 AM

Biosergen AB: Biosergen publishes interim report for the first quarter 2025

Press release5/12/2025, 11:45 AM

BioStock: Biosergen taps antifungal expert as board member

Regulatory press release5/9/2025, 1:14 PM

Biosergen AB: Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.